Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by davgroon Oct 12, 2022 10:44am
170 Views
Post# 35019494

RE:RE:NGL loving buying at these prices

RE:RE:NGL loving buying at these prices
Banana1234 wrote: What's your prediction for EOY price?

I think EOY stock price for ATE will depend on several factors:

  • General market conditions.  If market continues to drift lower it is envitable that ATE will follow suit with weak hands and low volume.
  • Year-end tax loss selling could also push the stock price lower.
  • Will results of any animal studies on the drug new formulation be released before year-end, and if so, will they actually move the needle ?  Unlikely.
  • Unlikely that new formulation patent application will be approved prior to year-end.

Based on today's muted market response to ATE's news release I would anticipate a lower EOY price for the stock, quite possibly in the low $.50s.  I see no significant price movement in the stock until 2023 now.  As Mugsy said, investors will likely wait for analyst comments and any revised target prices, based on today's news release, before making concrete decisions on their ATE holdings.

JMO
<< Previous
Bullboard Posts
Next >>